

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
07 May 2020 (07.05.2020)



(10) International Publication Number
WO 2020/088459 A1

(51) International Patent Classification:

C07K 19/00 (2006.01) C12N 15/63 (2006.01)
C07K 14/715 (2006.01) A61K 38/17 (2006.01)
C07K 16/28 (2006.01) A61P 35/00 (2006.01)
C12N 15/62 (2006.01)

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/CN2019/114026

(22) International Filing Date:

29 October 2019 (29.10.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/752,293 29 October 2018 (29.10.2018) US
62/811,116 27 February 2019 (27.02.2019) US

(71) Applicants: **IGLOBE BIOMEDICAL CO., LTD.**
[CN/CN]; 8F, Block B, Techart Plaza, No. 30 Xueyuan
Road, Haidian District, Beijing 100083 (CN). **IGLOBE
HEALTH INSTITUTE LLC** [US/US]; 333 Providence
Hwy, Norwood, Massachusetts 02062 (US).

(72) Inventors: **LI, Chiang J**; c/o IGLOBE HEALTH INSTI-
TUTE LLC, 333 Providence Highway, Norwood, Mass-
achusetts 02062 (US). **UNNIRAMAN, Shyam**; Newton,
Massachusetts 02465 (US). **BADER, Hannah**; Waltham,
Massachusetts 02451 (US). **LAU, Alan**; Malden, Massa-
chusetts 02148 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: NOVEL RATIONALLY DESIGNED PROTEIN COMPOSITIONS

(57) Abstract: Novel compositions and methods relating to or derived from a rationally designed fusion protein composition combines a therapeutic antibody with an IL2 mutant that can simultaneously enhance anti-tumor immunity or derepress tumor-associated immunosuppression along with direct activation of effector cells by IL2 without activating T_{reg} are provided. The fusion protein can be used to prevent or therapeutically treat cancer.

WO 2020/088459 A1